ImmunomeIMNM
IMNM
About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Employees: 118
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
4% more funds holding
Funds holding: 114 [Q3] → 119 (+5) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
0.57% less ownership
Funds ownership: 85.97% [Q3] → 85.41% (-0.57%) [Q4]
25% less capital invested
Capital invested by funds: $755M [Q3] → $566M (-$188M) [Q4]
98% less call options, than puts
Call options by funds: $439K | Put options by funds: $21.9M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
153%
upside
Avg. target
$26
231%
upside
High target
$33
317%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Chad Messer 67% 1-year accuracy 2 / 3 met price target | 191%upside $23 | Buy Initiated | 2 Apr 2025 |
Wedbush David Nierengarten 34% 1-year accuracy 40 / 119 met price target | 317%upside $33 | Outperform Reiterated | 20 Mar 2025 |
Stephens & Co. Sudan Loganathan 15% 1-year accuracy 4 / 27 met price target | 279%upside $30 | Overweight Reiterated | 20 Mar 2025 |
Guggenheim Michael Schmidt 27% 1-year accuracy 10 / 37 met price target | 216%upside $25 | Buy Maintained | 20 Mar 2025 |
LifeSci Capital | 153%upside $20 | Outperform Initiated | 11 Mar 2025 |
Financial journalist opinion
Based on 3 articles about IMNM published over the past 30 days
Positive
Seeking Alpha
2 days ago
Immunome: Transformed Pipeline Offers Multiple Catalysts
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts.
Neutral
Business Wire
2 weeks ago
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww.
Neutral
Business Wire
2 weeks ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Induce.
Negative
Zacks Investment Research
1 month ago
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago.
Neutral
Business Wire
1 month ago
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. “Immunome's efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We are pleased with the progress of our pipeline and, with multiple.
Neutral
Business Wire
1 month ago
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021.
Neutral
Business Wire
1 month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 49,000 shares of common stock to four new employees under the Company's 2024 Inducem.
Neutral
Business Wire
1 month ago
Immunome to Present at Upcoming March Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/.
Neutral
Business Wire
2 months ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company's 2024 Indu.
Neutral
Business Wire
2 months ago
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo.
Charts implemented using Lightweight Charts™